Evidence map›Paper›PMID 37069784›Full record

Observational studyCancer reports (Hoboken, N.J.)2023

First-line cetuximab + platinum-based therapy for recurrent/metastatic head and neck squamous cell carcinoma: A real-world observational study-ENCORE.

Christophe Le Tourneau, Massimo Ghiani, Maria Chiara Cau, Roberta Depenni, Graziana Ronzino, Pierluigi Bonomo, Vincenzo Montesarchio, Luigi Leo, Jeltje Schulten, Satu Salmio and 4 more

Open access · goldAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Cancer reports (Hoboken, N.J.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.4field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Observational
  2. Article
  3. Review
  4. Article
  5. Review
  6. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 11 institutions in 4 countries.

Christophe Le TourneauDepartment of Drug Development and Innovation (D3i), Institut Curie, Paris, France.ORCID 0000-0001-9772-4686
Massimo GhianiDepartment of Oncology, Azienda Ospedaliera Brotzu, Cagliari, Italy.
Maria Chiara CauDepartment of Oncology, Azienda Ospedaliera Brotzu, Cagliari, Italy.
Roberta DepenniDepartment of Oncology and Hematology, Università degli Studi di Modena e Reggio Emilia, Modena, Italy.
Graziana RonzinoOncology Unit, Ospedale, Vito Fazzi, Lecce, Italy.
Pierluigi BonomoRadiation Oncology, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy.
Vincenzo MontesarchioAORN dei Colli, Monaldi Hospital, Naples, Italy.
Luigi LeoAORN dei Colli, Monaldi Hospital, Naples, Italy.
Jeltje SchultenGlobal Medical Unit Oncology, Merck Healthcare KGaA, Darmstadt, Germany.
Satu SalmioGlobal Medical Unit Oncology, Merck Healthcare KGaA, Darmstadt, Germany.
Diethelm MessingerStatistics, Prometris GmbH, Mannheim, Germany.
Andrea SbranaService of Pneumo-Oncology, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy.
Edith BorcomanDepartment of Drug Development and Innovation (D3i), Institut Curie, Paris, France.
Maria Grazia GhiOncology Unit 2, Istituto Oncologico Veneto-IRCCS, Padova, Italy.
Azienda Ospedaliera G. Brotzu · ITMerck (Germany) · DEOspedale Monaldi · ITAzienda Ospedaliero-Universitaria Careggi · ITInserm · FRInstitut Curie · FRIstituto Oncologico Veneto · ITOspedale Vito Fazzi · ITPromentis Pharmaceuticals (United States) · USUniversity of Modena and Reggio Emilia · ITUniversity of Pisa · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundENCORE, an observational, prospective, open-label study, investigated real-world treatment practices and outcomes with cetuximab plus platinum-based therapy (PBT) in first-line (1L) recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN).

aimsThis multinational study aimed to investigate the long-term use of cetuximab plus PBT for 1L R/M SCCHN in a clinical setting. In particular, this study aimed to explore clinical considerations such as the decision to prescribe cetuximab plus PBT in R/M SCCHN, the mode and duration of treatment, and patient outcomes. METHODS AND

resultsPreviously untreated patients with R/M SCCHN whose planned treatment was cetuximab plus PBT were enrolled from 6 countries. Among 221 evaluable patients, planned treatments included cetuximab plus carboplatin (31.2%), cisplatin plus 5-fluorouracil (31.7%), or carboplatin plus 5-fluorouracil (23.1%); 3.2% included a taxane, and 45.2% did not include 5-fluorouracil. Cetuximab treatment was planned for a fixed duration (≤24 weeks) in 15 patients (6.8%) and until disease progression in 206 (93.2%). Median progression-free survival and overall survival were 6.5 and 10.8 months, respectively. Grade ≥3 adverse events occurred in 39.8% of patients. Serious adverse events occurred in 25.8% of patients; 5.4% were cetuximab-related.

conclusionIn patients with R/M SCCHN, first-line cetuximab plus PBT was feasible and modifiable in a real-world setting with similar toxicity and efficacy as in the pivotal phase III EXTREME trial. CLINICAL TRIAL REGISTRATION NUMBER: EMR 062202-566.

Indexed as

Head and Neck NeoplasmsPlatinumCarboplatinCetuximabCisplatinFluorouracilHumansNeoplasm Recurrence, LocalProspective StudiesSquamous Cell Carcinoma of Head and NeckCarboplatinCetuximabCisplatinFluorouracilPlatinumcetuximabcombination chemotherapyfirst-lineobservational studysquamous cell carcinoma of head and neck

Identifiers

PMID37069784
PMCPMC10172179
OpenAlexW4366242353

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.